LPV/r 200+50mg heat/st tabs/PAC-120 gb

General Description
Lopinavir 200mg + Ritonavir 50mg film coated heat stable tablets, pack of 120
(gb = generic / bottle pack)

Technical Specifications
Each film coated tablet contains a fixed boosted protease inhibitor combination of Lopinavir 200mg + Ritonavir 50mg in a heat stable formulation.

Therapeutic class
Protease Inhibitors (PI)

Standard shelf life
2 years (24 months)

Other available formulations
The product may also be available in other formulations, pack sizes, or in combinations with other ARVs.

Guidelines for use
For more details, please see WHO treatment guidelines http://www.who.int/hiv/pub/guidelines/en/index.html and WHO Essential Medicines Library http://www.who.int/emlib/ or your regional/national guidelines.

Details about paediatric dosage schemes can be found at www.who.int/hiv/topics/paediatric/en/index.html

WHO generic tool for assessing paediatric ARV dosing
http://www.who.int/hiv/paediatric/generictool/en/

Indications
Management of HIV-1 infection in infected adults and children above 2 years of age in combination with at least two other antiretroviral drugs. By mouth (PO)
NOTE
Ritonavir increases effect of Lopinavir; it is used in this co-formulation as a booster to Lopinavir and this low dose in combination does not have intrinsic antiviral activity

Storage
Do not store above 30ºC (86°F)
Store in tightly closed original container
Keep out of reach and sight of children.

Dispensing instructions
Dispense in original container. Do not repack
Tablet should not be broken or crushed. Should be swallowed whole

Regulatory status
For latest updates check the list of ‘Prequalified Medicines’ on the WHO website ‘Prequalification Programme’. http://apps.who.int/prequal/

For latest updates check the list of ‘USFDA approved and tentatively approved’ items on the USFDA website. http://www.fda.gov/default.htm, http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/